世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

甲状腺乳頭癌治療の世界市場成長率 2023-2029


Global Papillary Thyroid Cancer Treatment Market Growth 2023-2029

世界の乳頭状甲状腺癌治療の市場規模は、2022年の2690.2百万米ドルから2029年には3780.2百万米ドルに成長すると予測され、2023年から2029年までのCAGRは5.0%と予測されています。 乳頭状甲状腺癌治療薬の米国市... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2023年6月14日 US$3,660
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
111 英語

 

サマリー

世界の乳頭状甲状腺癌治療の市場規模は、2022年の2690.2百万米ドルから2029年には3780.2百万米ドルに成長すると予測され、2023年から2029年までのCAGRは5.0%と予測されています。
乳頭状甲状腺癌治療薬の米国市場は、2023年から2029年までのCAGRで、2022年の100万米ドルから2029年には100万米ドルに増加すると予測されています。
乳頭状甲状腺癌治療の中国市場は、2023年から2029年までのCAGR %で、2022年の百万米ドルから2029年には百万米ドルに増加すると推定されます。
乳頭状甲状腺癌治療のヨーロッパ市場は、2023年から2029年までのCAGR %で、2022年の百万米ドルから2029年までに百万米ドルに増加すると推定されます。
世界の主要な乳頭状甲状腺癌治療のプレーヤーは、Mylan pharmaceuticals Inc.、Baxter International Inc.、Alara Pharmaceutical Corporation、Abbott laboratories、Bristol Myers co.、Teva parenteral medicines Inc.、Jerome Stevens Pharmaceuticals Inc.、メルクおよびノバルティスなどをカバーしています。収益面では、世界の2大企業が2022年にほぼ%のシェアを占めています。
甲状腺乳頭がんは、甲状腺がんの中で最も一般的なタイプであり、甲状腺がん全体の75%から85%を占めています。女性に多く発症し、20〜55歳の年齢層に発症します。また、小児甲状腺がんや、頭頸部に放射線照射を受けたことのある甲状腺がん患者さんでは、このタイプのがんが多くみられます。転移することもありますが、高分化型、低成長、限局型であることが多いです。
LPI(エルピーアイ)の最新リサーチレポート「甲状腺乳頭癌治療産業の予測」は、過去の売上高を調べ、2022年の世界の甲状腺乳頭癌治療の総売上高を検討し、2023年から2029年の甲状腺乳頭癌治療の予測売上を地域と市場分野ごとに包括的に分析しています。本レポートでは、乳頭状甲状腺癌治療の売上を地域別、市場分野別、サブセクター別に分類し、世界の乳頭状甲状腺癌治療産業の詳細な分析(百万米ドル単位)を提供します。
本インサイトレポートでは、世界の乳頭状甲状腺癌治療の状況を包括的に分析し、製品区分、会社設立、収益、市場シェア、最新開発、M&A活動に関する主要動向を明らかにします。また、本レポートでは、加速する世界のパピラリ甲状腺がん治療市場におけるこれらの企業の独自のポジションをより良く理解するために、パピラリ甲状腺がん治療のポートフォリオと能力、市場参入戦略、市場ポジション、地理的フットプリントに焦点を当てて、主要グローバル企業の戦略を分析しています。
本インサイトレポートでは、乳頭状甲状腺がん治療の世界的な見通しを形成する主要な市場動向、推進要因、影響要因を評価し、タイプ別、用途別、地域別、市場規模別に予測を行い、新たな機会のポケットを明らかにします。何百ものボトムアップの定性的・定量的な市場インプットに基づく透明性の高い手法により、この調査予測は、世界の乳頭状甲状腺癌治療の現状と将来の軌道について非常にニュアンスのある見方を提供します。
本レポートでは、製品タイプ、用途、主要メーカー、主要地域・国別に、甲状腺乳頭癌治療市場の包括的な概要、市場シェア、成長機会について紹介します。
市場のセグメンテーション
タイプ別セグメンテーション
手術療法
ヨード治療
サイロキシン治療
化学療法
その他
用途別セグメント
病院薬局
小売薬局
オンライン薬局
また、本レポートでは、地域別に市場を分割しています:
米州
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
欧州
ドイツ
フランス
イギリス
イタリア
ロシア
中近東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要な専門家から収集した情報、企業のカバレッジ、製品ポートフォリオ、市場浸透度を分析した上で選定されています。
マイラン・ファーマシューティカルズInc.
バクスター・インターナショナル・インク
アララ・ファーマシューティカル・コーポレーション
アボット ラボラトリーズ
ブリストル・マイヤーズ株式会社
テバ・ペレンタラル・メディシンズInc.
ジェローム・スティーブンス・ファーマシューティカルズInc.
メルク
ノバルティス
ファイザー
サノフィ
ギャラクソ・スミスクライン
バイオジェン・アイデック
バイエル ヘルスケア ファーマシューティカルズ
ジョンソン・エンド・ジョンソン
トレロ・ファーマシューティカル
本レポートで扱う主な質問
世界の甲状腺乳頭癌治療薬市場の10年後の展望は?
世界および地域別に、乳頭状甲状腺がん治療薬市場の成長を促進する要因は何か?
市場別、地域別に最も速い成長を遂げる技術は何か?
乳頭状甲状腺がん治療の市場機会は、エンドマーケットの規模によってどのように変化するのか?
乳頭状甲状腺がん治療薬のタイプ別、用途別内訳は?
COVID-19とロシア・ウクライナ戦争の影響とは?


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Papillary Thyroid Cancer Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Papillary Thyroid Cancer Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Papillary Thyroid Cancer Treatment by Country/Region, 2018, 2022 & 2029
2.2 Papillary Thyroid Cancer Treatment Segment by Type
2.2.1 Surgery
2.2.2 Iodine Therapy
2.2.3 Thyroxin Treatment
2.2.4 Chemotherapy
2.2.5 Others
2.3 Papillary Thyroid Cancer Treatment Sales by Type
2.3.1 Global Papillary Thyroid Cancer Treatment Sales Market Share by Type (2018-2023)
2.3.2 Global Papillary Thyroid Cancer Treatment Revenue and Market Share by Type (2018-2023)
2.3.3 Global Papillary Thyroid Cancer Treatment Sale Price by Type (2018-2023)
2.4 Papillary Thyroid Cancer Treatment Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Papillary Thyroid Cancer Treatment Sales by Application
2.5.1 Global Papillary Thyroid Cancer Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Papillary Thyroid Cancer Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Papillary Thyroid Cancer Treatment Sale Price by Application (2018-2023)
3 Global Papillary Thyroid Cancer Treatment by Company
3.1 Global Papillary Thyroid Cancer Treatment Breakdown Data by Company
3.1.1 Global Papillary Thyroid Cancer Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Papillary Thyroid Cancer Treatment Sales Market Share by Company (2018-2023)
3.2 Global Papillary Thyroid Cancer Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Papillary Thyroid Cancer Treatment Revenue by Company (2018-2023)
3.2.2 Global Papillary Thyroid Cancer Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Papillary Thyroid Cancer Treatment Sale Price by Company
3.4 Key Manufacturers Papillary Thyroid Cancer Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Papillary Thyroid Cancer Treatment Product Location Distribution
3.4.2 Players Papillary Thyroid Cancer Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Papillary Thyroid Cancer Treatment by Geographic Region
4.1 World Historic Papillary Thyroid Cancer Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Papillary Thyroid Cancer Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Papillary Thyroid Cancer Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Papillary Thyroid Cancer Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Papillary Thyroid Cancer Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Papillary Thyroid Cancer Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Papillary Thyroid Cancer Treatment Sales Growth
4.4 APAC Papillary Thyroid Cancer Treatment Sales Growth
4.5 Europe Papillary Thyroid Cancer Treatment Sales Growth
4.6 Middle East & Africa Papillary Thyroid Cancer Treatment Sales Growth
5 Americas
5.1 Americas Papillary Thyroid Cancer Treatment Sales by Country
5.1.1 Americas Papillary Thyroid Cancer Treatment Sales by Country (2018-2023)
5.1.2 Americas Papillary Thyroid Cancer Treatment Revenue by Country (2018-2023)
5.2 Americas Papillary Thyroid Cancer Treatment Sales by Type
5.3 Americas Papillary Thyroid Cancer Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Papillary Thyroid Cancer Treatment Sales by Region
6.1.1 APAC Papillary Thyroid Cancer Treatment Sales by Region (2018-2023)
6.1.2 APAC Papillary Thyroid Cancer Treatment Revenue by Region (2018-2023)
6.2 APAC Papillary Thyroid Cancer Treatment Sales by Type
6.3 APAC Papillary Thyroid Cancer Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Papillary Thyroid Cancer Treatment by Country
7.1.1 Europe Papillary Thyroid Cancer Treatment Sales by Country (2018-2023)
7.1.2 Europe Papillary Thyroid Cancer Treatment Revenue by Country (2018-2023)
7.2 Europe Papillary Thyroid Cancer Treatment Sales by Type
7.3 Europe Papillary Thyroid Cancer Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Papillary Thyroid Cancer Treatment by Country
8.1.1 Middle East & Africa Papillary Thyroid Cancer Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Papillary Thyroid Cancer Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Papillary Thyroid Cancer Treatment Sales by Type
8.3 Middle East & Africa Papillary Thyroid Cancer Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Papillary Thyroid Cancer Treatment
10.3 Manufacturing Process Analysis of Papillary Thyroid Cancer Treatment
10.4 Industry Chain Structure of Papillary Thyroid Cancer Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Papillary Thyroid Cancer Treatment Distributors
11.3 Papillary Thyroid Cancer Treatment Customer
12 World Forecast Review for Papillary Thyroid Cancer Treatment by Geographic Region
12.1 Global Papillary Thyroid Cancer Treatment Market Size Forecast by Region
12.1.1 Global Papillary Thyroid Cancer Treatment Forecast by Region (2024-2029)
12.1.2 Global Papillary Thyroid Cancer Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Papillary Thyroid Cancer Treatment Forecast by Type
12.7 Global Papillary Thyroid Cancer Treatment Forecast by Application
13 Key Players Analysis
13.1 Mylan pharmaceuticals Inc.
13.1.1 Mylan pharmaceuticals Inc. Company Information
13.1.2 Mylan pharmaceuticals Inc. Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.1.3 Mylan pharmaceuticals Inc. Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Mylan pharmaceuticals Inc. Main Business Overview
13.1.5 Mylan pharmaceuticals Inc. Latest Developments
13.2 Baxter International Inc.
13.2.1 Baxter International Inc. Company Information
13.2.2 Baxter International Inc. Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.2.3 Baxter International Inc. Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Baxter International Inc. Main Business Overview
13.2.5 Baxter International Inc. Latest Developments
13.3 Alara Pharmaceutical Corporation
13.3.1 Alara Pharmaceutical Corporation Company Information
13.3.2 Alara Pharmaceutical Corporation Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.3.3 Alara Pharmaceutical Corporation Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Alara Pharmaceutical Corporation Main Business Overview
13.3.5 Alara Pharmaceutical Corporation Latest Developments
13.4 Abbott laboratories
13.4.1 Abbott laboratories Company Information
13.4.2 Abbott laboratories Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.4.3 Abbott laboratories Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Abbott laboratories Main Business Overview
13.4.5 Abbott laboratories Latest Developments
13.5 Bristol Myers co.
13.5.1 Bristol Myers co. Company Information
13.5.2 Bristol Myers co. Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.5.3 Bristol Myers co. Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Bristol Myers co. Main Business Overview
13.5.5 Bristol Myers co. Latest Developments
13.6 Teva parenteral medicines Inc.
13.6.1 Teva parenteral medicines Inc. Company Information
13.6.2 Teva parenteral medicines Inc. Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.6.3 Teva parenteral medicines Inc. Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Teva parenteral medicines Inc. Main Business Overview
13.6.5 Teva parenteral medicines Inc. Latest Developments
13.7 Jerome Stevens Pharmaceuticals Inc.
13.7.1 Jerome Stevens Pharmaceuticals Inc. Company Information
13.7.2 Jerome Stevens Pharmaceuticals Inc. Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.7.3 Jerome Stevens Pharmaceuticals Inc. Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Jerome Stevens Pharmaceuticals Inc. Main Business Overview
13.7.5 Jerome Stevens Pharmaceuticals Inc. Latest Developments
13.8 Merck
13.8.1 Merck Company Information
13.8.2 Merck Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.8.3 Merck Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Merck Main Business Overview
13.8.5 Merck Latest Developments
13.9 Novartis
13.9.1 Novartis Company Information
13.9.2 Novartis Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.9.3 Novartis Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Novartis Main Business Overview
13.9.5 Novartis Latest Developments
13.10 Pfizer
13.10.1 Pfizer Company Information
13.10.2 Pfizer Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.10.3 Pfizer Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Pfizer Main Business Overview
13.10.5 Pfizer Latest Developments
13.11 Sanofi
13.11.1 Sanofi Company Information
13.11.2 Sanofi Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.11.3 Sanofi Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Sanofi Main Business Overview
13.11.5 Sanofi Latest Developments
13.12 GalaxoSmithKline
13.12.1 GalaxoSmithKline Company Information
13.12.2 GalaxoSmithKline Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.12.3 GalaxoSmithKline Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 GalaxoSmithKline Main Business Overview
13.12.5 GalaxoSmithKline Latest Developments
13.13 Biogen Idec
13.13.1 Biogen Idec Company Information
13.13.2 Biogen Idec Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.13.3 Biogen Idec Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Biogen Idec Main Business Overview
13.13.5 Biogen Idec Latest Developments
13.14 Bayer Healthcare Pharmaceuticals
13.14.1 Bayer Healthcare Pharmaceuticals Company Information
13.14.2 Bayer Healthcare Pharmaceuticals Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.14.3 Bayer Healthcare Pharmaceuticals Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Bayer Healthcare Pharmaceuticals Main Business Overview
13.14.5 Bayer Healthcare Pharmaceuticals Latest Developments
13.15 Johnson & Johnson
13.15.1 Johnson & Johnson Company Information
13.15.2 Johnson & Johnson Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.15.3 Johnson & Johnson Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Johnson & Johnson Main Business Overview
13.15.5 Johnson & Johnson Latest Developments
13.16 Tolero Pharmaceutical
13.16.1 Tolero Pharmaceutical Company Information
13.16.2 Tolero Pharmaceutical Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.16.3 Tolero Pharmaceutical Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Tolero Pharmaceutical Main Business Overview
13.16.5 Tolero Pharmaceutical Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

The global Papillary Thyroid Cancer Treatment market size is projected to grow from US$ 2690.2 million in 2022 to US$ 3780.2 million in 2029; it is expected to grow at a CAGR of 5.0% from 2023 to 2029.
United States market for Papillary Thyroid Cancer Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Papillary Thyroid Cancer Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Papillary Thyroid Cancer Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Papillary Thyroid Cancer Treatment players cover Mylan pharmaceuticals Inc., Baxter International Inc., Alara Pharmaceutical Corporation, Abbott laboratories, Bristol Myers co., Teva parenteral medicines Inc., Jerome Stevens Pharmaceuticals Inc., Merck and Novartis, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Papillary Thyroid Cancer is the most common type of thyroid cancer, representing 75 percent to 85 percent of all thyroid cancer cases. It occurs more frequently in women and presents in the 20–55 year age group. It is also the predominant cancer type in children with thyroid cancer, and in patients with thyroid cancer who have had previous radiation to the head and neck. It is often well-differentiated, slow-growing, and localized, although it can metastasize.
LPI (LP Information)' newest research report, the “Papillary Thyroid Cancer Treatment Industry Forecast” looks at past sales and reviews total world Papillary Thyroid Cancer Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Papillary Thyroid Cancer Treatment sales for 2023 through 2029. With Papillary Thyroid Cancer Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Papillary Thyroid Cancer Treatment industry.
This Insight Report provides a comprehensive analysis of the global Papillary Thyroid Cancer Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Papillary Thyroid Cancer Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Papillary Thyroid Cancer Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Papillary Thyroid Cancer Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Papillary Thyroid Cancer Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Papillary Thyroid Cancer Treatment market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Surgery
Iodine Therapy
Thyroxin Treatment
Chemotherapy
Others
Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Mylan pharmaceuticals Inc.
Baxter International Inc.
Alara Pharmaceutical Corporation
Abbott laboratories
Bristol Myers co.
Teva parenteral medicines Inc.
Jerome Stevens Pharmaceuticals Inc.
Merck
Novartis
Pfizer
Sanofi
GalaxoSmithKline
Biogen Idec
Bayer Healthcare Pharmaceuticals
Johnson & Johnson
Tolero Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Papillary Thyroid Cancer Treatment market?
What factors are driving Papillary Thyroid Cancer Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Papillary Thyroid Cancer Treatment market opportunities vary by end market size?
How does Papillary Thyroid Cancer Treatment break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Papillary Thyroid Cancer Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Papillary Thyroid Cancer Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Papillary Thyroid Cancer Treatment by Country/Region, 2018, 2022 & 2029
2.2 Papillary Thyroid Cancer Treatment Segment by Type
2.2.1 Surgery
2.2.2 Iodine Therapy
2.2.3 Thyroxin Treatment
2.2.4 Chemotherapy
2.2.5 Others
2.3 Papillary Thyroid Cancer Treatment Sales by Type
2.3.1 Global Papillary Thyroid Cancer Treatment Sales Market Share by Type (2018-2023)
2.3.2 Global Papillary Thyroid Cancer Treatment Revenue and Market Share by Type (2018-2023)
2.3.3 Global Papillary Thyroid Cancer Treatment Sale Price by Type (2018-2023)
2.4 Papillary Thyroid Cancer Treatment Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Papillary Thyroid Cancer Treatment Sales by Application
2.5.1 Global Papillary Thyroid Cancer Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Papillary Thyroid Cancer Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Papillary Thyroid Cancer Treatment Sale Price by Application (2018-2023)
3 Global Papillary Thyroid Cancer Treatment by Company
3.1 Global Papillary Thyroid Cancer Treatment Breakdown Data by Company
3.1.1 Global Papillary Thyroid Cancer Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Papillary Thyroid Cancer Treatment Sales Market Share by Company (2018-2023)
3.2 Global Papillary Thyroid Cancer Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Papillary Thyroid Cancer Treatment Revenue by Company (2018-2023)
3.2.2 Global Papillary Thyroid Cancer Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Papillary Thyroid Cancer Treatment Sale Price by Company
3.4 Key Manufacturers Papillary Thyroid Cancer Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Papillary Thyroid Cancer Treatment Product Location Distribution
3.4.2 Players Papillary Thyroid Cancer Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Papillary Thyroid Cancer Treatment by Geographic Region
4.1 World Historic Papillary Thyroid Cancer Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Papillary Thyroid Cancer Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Papillary Thyroid Cancer Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Papillary Thyroid Cancer Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Papillary Thyroid Cancer Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Papillary Thyroid Cancer Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Papillary Thyroid Cancer Treatment Sales Growth
4.4 APAC Papillary Thyroid Cancer Treatment Sales Growth
4.5 Europe Papillary Thyroid Cancer Treatment Sales Growth
4.6 Middle East & Africa Papillary Thyroid Cancer Treatment Sales Growth
5 Americas
5.1 Americas Papillary Thyroid Cancer Treatment Sales by Country
5.1.1 Americas Papillary Thyroid Cancer Treatment Sales by Country (2018-2023)
5.1.2 Americas Papillary Thyroid Cancer Treatment Revenue by Country (2018-2023)
5.2 Americas Papillary Thyroid Cancer Treatment Sales by Type
5.3 Americas Papillary Thyroid Cancer Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Papillary Thyroid Cancer Treatment Sales by Region
6.1.1 APAC Papillary Thyroid Cancer Treatment Sales by Region (2018-2023)
6.1.2 APAC Papillary Thyroid Cancer Treatment Revenue by Region (2018-2023)
6.2 APAC Papillary Thyroid Cancer Treatment Sales by Type
6.3 APAC Papillary Thyroid Cancer Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Papillary Thyroid Cancer Treatment by Country
7.1.1 Europe Papillary Thyroid Cancer Treatment Sales by Country (2018-2023)
7.1.2 Europe Papillary Thyroid Cancer Treatment Revenue by Country (2018-2023)
7.2 Europe Papillary Thyroid Cancer Treatment Sales by Type
7.3 Europe Papillary Thyroid Cancer Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Papillary Thyroid Cancer Treatment by Country
8.1.1 Middle East & Africa Papillary Thyroid Cancer Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Papillary Thyroid Cancer Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Papillary Thyroid Cancer Treatment Sales by Type
8.3 Middle East & Africa Papillary Thyroid Cancer Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Papillary Thyroid Cancer Treatment
10.3 Manufacturing Process Analysis of Papillary Thyroid Cancer Treatment
10.4 Industry Chain Structure of Papillary Thyroid Cancer Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Papillary Thyroid Cancer Treatment Distributors
11.3 Papillary Thyroid Cancer Treatment Customer
12 World Forecast Review for Papillary Thyroid Cancer Treatment by Geographic Region
12.1 Global Papillary Thyroid Cancer Treatment Market Size Forecast by Region
12.1.1 Global Papillary Thyroid Cancer Treatment Forecast by Region (2024-2029)
12.1.2 Global Papillary Thyroid Cancer Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Papillary Thyroid Cancer Treatment Forecast by Type
12.7 Global Papillary Thyroid Cancer Treatment Forecast by Application
13 Key Players Analysis
13.1 Mylan pharmaceuticals Inc.
13.1.1 Mylan pharmaceuticals Inc. Company Information
13.1.2 Mylan pharmaceuticals Inc. Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.1.3 Mylan pharmaceuticals Inc. Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Mylan pharmaceuticals Inc. Main Business Overview
13.1.5 Mylan pharmaceuticals Inc. Latest Developments
13.2 Baxter International Inc.
13.2.1 Baxter International Inc. Company Information
13.2.2 Baxter International Inc. Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.2.3 Baxter International Inc. Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Baxter International Inc. Main Business Overview
13.2.5 Baxter International Inc. Latest Developments
13.3 Alara Pharmaceutical Corporation
13.3.1 Alara Pharmaceutical Corporation Company Information
13.3.2 Alara Pharmaceutical Corporation Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.3.3 Alara Pharmaceutical Corporation Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Alara Pharmaceutical Corporation Main Business Overview
13.3.5 Alara Pharmaceutical Corporation Latest Developments
13.4 Abbott laboratories
13.4.1 Abbott laboratories Company Information
13.4.2 Abbott laboratories Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.4.3 Abbott laboratories Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Abbott laboratories Main Business Overview
13.4.5 Abbott laboratories Latest Developments
13.5 Bristol Myers co.
13.5.1 Bristol Myers co. Company Information
13.5.2 Bristol Myers co. Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.5.3 Bristol Myers co. Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Bristol Myers co. Main Business Overview
13.5.5 Bristol Myers co. Latest Developments
13.6 Teva parenteral medicines Inc.
13.6.1 Teva parenteral medicines Inc. Company Information
13.6.2 Teva parenteral medicines Inc. Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.6.3 Teva parenteral medicines Inc. Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Teva parenteral medicines Inc. Main Business Overview
13.6.5 Teva parenteral medicines Inc. Latest Developments
13.7 Jerome Stevens Pharmaceuticals Inc.
13.7.1 Jerome Stevens Pharmaceuticals Inc. Company Information
13.7.2 Jerome Stevens Pharmaceuticals Inc. Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.7.3 Jerome Stevens Pharmaceuticals Inc. Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Jerome Stevens Pharmaceuticals Inc. Main Business Overview
13.7.5 Jerome Stevens Pharmaceuticals Inc. Latest Developments
13.8 Merck
13.8.1 Merck Company Information
13.8.2 Merck Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.8.3 Merck Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Merck Main Business Overview
13.8.5 Merck Latest Developments
13.9 Novartis
13.9.1 Novartis Company Information
13.9.2 Novartis Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.9.3 Novartis Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Novartis Main Business Overview
13.9.5 Novartis Latest Developments
13.10 Pfizer
13.10.1 Pfizer Company Information
13.10.2 Pfizer Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.10.3 Pfizer Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Pfizer Main Business Overview
13.10.5 Pfizer Latest Developments
13.11 Sanofi
13.11.1 Sanofi Company Information
13.11.2 Sanofi Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.11.3 Sanofi Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Sanofi Main Business Overview
13.11.5 Sanofi Latest Developments
13.12 GalaxoSmithKline
13.12.1 GalaxoSmithKline Company Information
13.12.2 GalaxoSmithKline Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.12.3 GalaxoSmithKline Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 GalaxoSmithKline Main Business Overview
13.12.5 GalaxoSmithKline Latest Developments
13.13 Biogen Idec
13.13.1 Biogen Idec Company Information
13.13.2 Biogen Idec Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.13.3 Biogen Idec Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Biogen Idec Main Business Overview
13.13.5 Biogen Idec Latest Developments
13.14 Bayer Healthcare Pharmaceuticals
13.14.1 Bayer Healthcare Pharmaceuticals Company Information
13.14.2 Bayer Healthcare Pharmaceuticals Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.14.3 Bayer Healthcare Pharmaceuticals Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Bayer Healthcare Pharmaceuticals Main Business Overview
13.14.5 Bayer Healthcare Pharmaceuticals Latest Developments
13.15 Johnson & Johnson
13.15.1 Johnson & Johnson Company Information
13.15.2 Johnson & Johnson Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.15.3 Johnson & Johnson Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Johnson & Johnson Main Business Overview
13.15.5 Johnson & Johnson Latest Developments
13.16 Tolero Pharmaceutical
13.16.1 Tolero Pharmaceutical Company Information
13.16.2 Tolero Pharmaceutical Papillary Thyroid Cancer Treatment Product Portfolios and Specifications
13.16.3 Tolero Pharmaceutical Papillary Thyroid Cancer Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Tolero Pharmaceutical Main Business Overview
13.16.5 Tolero Pharmaceutical Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(cancer)の最新刊レポート


よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14 10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る